Roche said this week that it has signed a co-marketing deal with London-based pathology and molecular diagnostic lab Unilabs-IHS to provide Roche's Cobas HPV test to women in the UK.
Unilabs will provide the test as a follow-up to traditional Pap cervical smears and, upon request, as a primary screen for cervical pre-cancer.
The Cobas HPV test runs on the company's Cobas 4800 automated molecular testing system and individually identifies genotypes 16 and 18, the highest risk types associated with the development of cervical cancer and its precursor lesions, as well as 12 other high-risk HPV types as a pooled result.
Roche launched the assay in 2009 in countries that accept the CE Mark. The US Food and Drug Administration cleared the assay for marketing in April 2011.